Bartlett & Co’s Checkpoint Therapeutics CKPT Stock Holding History

Bartlett & Co’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$9K	Sell	4,000 -1,000	-20%	-$2.18K	﹤0.01%	1013
2023 Q3	$9K	Hold	5,000	–	–	﹤0.01%	935
2023 Q2	$12K	Hold	5,000	–	–	﹤0.01%	897
2023 Q1	$11K	Hold	5,000	–	–	﹤0.01%	802
2022 Q4	$26K	Hold	5,000	–	–	﹤0.01%	669
2022 Q3	$52K	Hold	5,000	–	–	﹤0.01%	557
2022 Q2	$52K	Hold	5,000	–	–	﹤0.01%	563
2022 Q1	$89K	Hold	5,000	–	–	﹤0.01%	501
2021 Q4	$156K	Buy	+5,000	New	+$166K	﹤0.01%	399

Other funds holding CKPT

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bartlett & Co's CKPT Position: Q4 2023 in Review

Bartlett & Co reduced its Checkpoint Therapeutics (CKPT) stake by 20% in Q4 2023, selling an estimated $2.18K and leaving 4,000 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #1013.

Bartlett & Co first reported a position in CKPT in Q4 2021 and has held it in 9 quarters since. The position peaked at $156K in Q4 2021. 43 funds tracked by Wall St. Rank hold CKPT as of Q4 2023.

Bartlett & Co held 4,000 shares of Checkpoint Therapeutics worth $9K as of Q4 2023.
Bartlett & Co sold 1,000 Checkpoint Therapeutics shares in Q4 2023, an estimated $2.18K.
Checkpoint Therapeutics made up ﹤0.01% of Bartlett & Co's portfolio in Q4 2023, its #1013 holding.
Bartlett & Co first reported a position in Checkpoint Therapeutics in Q4 2021 and has held it in 9 quarters since.
Bartlett & Co's Checkpoint Therapeutics position peaked at $156K in Q4 2021.
43 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q4 2023.

Based on Bartlett & Co's 13F filing for Q4 2023, filed 8 Jan 2024.